LT3262932T - Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu - Google Patents

Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu

Info

Publication number
LT3262932T
LT3262932T LTEP17184955.7T LT17184955T LT3262932T LT 3262932 T LT3262932 T LT 3262932T LT 17184955 T LT17184955 T LT 17184955T LT 3262932 T LT3262932 T LT 3262932T
Authority
LT
Lithuania
Prior art keywords
genetically modified
major histocompatibility
histocompatibility complex
modified major
complex mice
Prior art date
Application number
LTEP17184955.7T
Other languages
English (en)
Inventor
Lynn Macdonald
Andrew J. Murphy
Cagan Gurer
John Mcwhirter
Vera VORONINA
Faith HARRIS
Sean Stevens
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3262932T publication Critical patent/LT3262932T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278Knock-in vertebrates, e.g. humanised vertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/072Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/15Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LTEP17184955.7T 2011-10-28 2012-10-26 Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu LT3262932T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552587P 2011-10-28 2011-10-28
US201161552582P 2011-10-28 2011-10-28
US201261700908P 2012-09-14 2012-09-14

Publications (1)

Publication Number Publication Date
LT3262932T true LT3262932T (lt) 2019-08-26

Family

ID=47178940

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP12787255.4T LT2770821T (lt) 2011-10-28 2012-10-26 Genetiškai modifikuotą didįjį audinių dermės kompleksą turinčios pelės
LTEP17184955.7T LT3262932T (lt) 2011-10-28 2012-10-26 Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP12787255.4T LT2770821T (lt) 2011-10-28 2012-10-26 Genetiškai modifikuotą didįjį audinių dermės kompleksą turinčios pelės

Country Status (25)

Country Link
US (3) US9615550B2 (lt)
EP (4) EP3563680B1 (lt)
JP (4) JP6154391B2 (lt)
KR (3) KR102295746B1 (lt)
CN (3) CN113564188A (lt)
AU (3) AU2012324016C1 (lt)
BR (1) BR112014009259A2 (lt)
CA (2) CA2850387A1 (lt)
CY (2) CY1119657T1 (lt)
DK (2) DK3262932T3 (lt)
ES (3) ES2962287T3 (lt)
HK (2) HK1200272A1 (lt)
HR (2) HRP20171761T1 (lt)
HU (2) HUE035652T2 (lt)
IL (3) IL232097A (lt)
LT (2) LT2770821T (lt)
MX (2) MX355725B (lt)
MY (2) MY164836A (lt)
NZ (1) NZ734532A (lt)
PL (2) PL3262932T3 (lt)
PT (2) PT3262932T (lt)
RS (2) RS56656B1 (lt)
SG (2) SG10201603188SA (lt)
SI (2) SI3262932T1 (lt)
WO (1) WO2013063346A1 (lt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6120451B2 (ja) 2011-10-28 2017-04-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ヒト化il−6および/またはil−6受容体
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
PL2958938T3 (pl) 2013-02-20 2019-11-29 Regeneron Pharma Myszy eksprymujące humanizowane ko-receptory komórek t
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
PL2958937T3 (pl) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
JP6456351B2 (ja) * 2013-03-11 2019-01-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. キメラ主要組織適合複合体(mhc)クラスi分子を発現する遺伝子導入マウス
RS64573B1 (sr) 2013-09-23 2023-10-31 Regeneron Pharma Ne-humana životinja sa humanizovanim signalno-regulatornim proteinskim genom
EP3461331A1 (en) 2013-10-15 2019-04-03 Regeneron Pharmaceuticals, Inc. Humanized il-15 animals
US10278373B2 (en) 2013-10-18 2019-05-07 Taiho Pharmaceutical Co., Ltd. HLA class I-expressing non-human animal
CN111690052B (zh) 2014-04-08 2024-06-04 瑞泽恩制药公司 具有人源化FC-γ受体的非人动物
RU2020103811A (ru) 2014-05-05 2020-02-18 Регенерон Фармасьютикалз, Инк. Гуманизированные животные по с5 и с3
NO2785538T3 (lt) 2014-05-07 2018-08-04
PT3157956T (pt) 2014-06-19 2020-04-09 Regeneron Pharma Animais não humanos com um gene 1 de morte programada humanizada em células
BR112017005245A2 (pt) 2014-09-19 2017-12-12 Regeneron Pharma animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.
RS63410B1 (sr) 2014-11-24 2022-08-31 Regeneron Pharma Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
KR102313073B1 (ko) 2014-12-05 2021-10-18 리제너론 파마슈티칼스 인코포레이티드 인간화 분화 클러스터 47 유전자를 가진 비인간 동물
AU2015360667B2 (en) * 2014-12-09 2021-09-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
KR102656470B1 (ko) * 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
RU2732628C2 (ru) 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
PT3282835T (pt) * 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
US10306874B2 (en) 2015-11-20 2019-06-04 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
KR102493894B1 (ko) 2016-02-29 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 인간화 tmprss 유전자를 갖는 설치류
CN116458475A (zh) 2016-06-03 2023-07-21 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
CN109456942A (zh) * 2017-09-06 2019-03-12 亘喜生物科技(上海)有限公司 通用型嵌合抗原受体t细胞制备技术
DK3687287T3 (da) * 2017-09-29 2023-10-16 Regeneron Pharma Gnavere, udtrykkende humaniseret c1q-kompleks
MX2020003589A (es) 2017-09-29 2020-07-22 Regeneron Pharma Animales no humanos que comprenden un locus ttr humanizado y metodos de uso.
SG11202002456WA (en) 2017-11-30 2020-04-29 Regeneron Pharma Non-human animals comprising a humanized trkb locus
CN112040769B (zh) * 2018-03-24 2023-05-16 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
CA3098040A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
CA3133360A1 (en) 2019-04-04 2020-10-08 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
AU2020289581A1 (en) 2019-06-07 2021-11-18 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
JP2023509082A (ja) * 2020-01-10 2023-03-06 バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド ヒト又はキメラmhcタンパク質複合体を有する遺伝子組換え非ヒト動物
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
WO2022133155A1 (en) * 2020-12-16 2022-06-23 Xenotherapeutics, Inc. Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs
CN116981357A (zh) 2021-03-31 2023-10-31 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024064860A1 (en) 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0950707B1 (en) 1989-07-25 2009-02-18 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
AU728794B2 (en) 1996-03-05 2001-01-18 Scripps Research Institute, The Recombinant constructs encoding T cell receptors specific for human HLA-restricted tumor antigens
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
AU1023401A (en) * 1999-10-12 2001-04-23 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050050580A1 (en) * 2000-12-13 2005-03-03 Masashi Gotoh Transgenic animal expressing hla-a24 and utilization thereof
AU2002246733B2 (en) 2000-12-19 2007-09-20 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
FR2827302B1 (fr) * 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
US7745690B2 (en) 2004-03-09 2010-06-29 Nagoya Industrial Science Research Institute Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
JP4830139B2 (ja) * 2006-03-10 2011-12-07 学校法人明治大学 クローン胚の作製方法
NZ547859A (en) * 2006-06-09 2009-05-31 Dec Int Nz Ltd Treatment method and composition for mastitis
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
EP1878342A1 (en) * 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
CN101986783A (zh) * 2007-04-23 2011-03-16 先灵公司 抗mdl-1抗体
WO2009114400A1 (en) 2008-03-07 2009-09-17 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
EP2153845A1 (en) * 2008-08-13 2010-02-17 Julius-Maximilians-Universität Würzburg Endoglin peptides, vaccines and methods for preparing the same
DK3028564T5 (da) * 2009-07-08 2024-04-29 Kymab Ltd Dyremodeller og terapeutiske molekyler
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
PL2958938T3 (pl) 2013-02-20 2019-11-29 Regeneron Pharma Myszy eksprymujące humanizowane ko-receptory komórek t
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
PL2958937T3 (pl) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Myszy ekspresjonujące humanizowany główny układ zgodności tkankowej
BR112015030211A2 (pt) * 2013-06-03 2017-08-22 Theravectys Vetores lentivirais contendo uma sequência promotora a montante da mhc de classe i, mhc de classe ii ou microglobulina beta-2
US10278373B2 (en) * 2013-10-18 2019-05-07 Taiho Pharmaceutical Co., Ltd. HLA class I-expressing non-human animal
RU2732628C2 (ru) 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных

Also Published As

Publication number Publication date
SG11201400933VA (en) 2014-04-28
MX2014004895A (es) 2014-09-12
US10869466B2 (en) 2020-12-22
JP6866409B2 (ja) 2021-04-28
NZ734532A (en) 2022-12-23
KR20200013810A (ko) 2020-02-07
IL232097A0 (en) 2014-05-28
IL232097A (en) 2017-06-29
RS56656B1 (sr) 2018-03-30
EP3563680B1 (en) 2023-08-30
EP2770821A1 (en) 2014-09-03
KR102295746B1 (ko) 2021-09-01
CY1119657T1 (el) 2018-04-04
EP4311833A2 (en) 2024-01-31
CA2850387A1 (en) 2013-05-02
AU2012324016A1 (en) 2013-05-16
JP6154391B2 (ja) 2017-06-28
CA3074400A1 (en) 2013-05-02
AU2017279797C1 (en) 2021-07-15
HRP20191420T1 (hr) 2019-11-15
DK3262932T3 (da) 2019-08-05
EP3262932A1 (en) 2018-01-03
EP3563680C0 (en) 2023-08-30
LT2770821T (lt) 2017-12-11
CY1121869T1 (el) 2020-10-14
KR20140089560A (ko) 2014-07-15
ES2962287T3 (es) 2024-03-18
CN113564188A (zh) 2021-10-29
CN107254480B (zh) 2021-08-10
US9615550B2 (en) 2017-04-11
HK1200272A1 (en) 2015-08-07
JP2019068857A (ja) 2019-05-09
KR102074145B1 (ko) 2020-02-07
JP2020146041A (ja) 2020-09-17
MX2020010763A (es) 2022-04-01
IL261239B (en) 2019-11-28
ES2741649T3 (es) 2020-02-11
AU2016202688B2 (en) 2017-09-28
CN107254480A (zh) 2017-10-17
EP2770821B1 (en) 2017-09-13
SI2770821T1 (en) 2018-01-31
SG10201603188SA (en) 2016-05-30
CN104039132B (zh) 2017-06-16
DK2770821T3 (da) 2017-11-27
HUE045879T2 (hu) 2020-01-28
US20130111617A1 (en) 2013-05-02
CN104039132A (zh) 2014-09-10
AU2017279797A1 (en) 2018-01-25
AU2016202688A1 (en) 2016-05-19
CN104039132B9 (zh) 2017-09-05
MY164836A (en) 2018-01-30
MX355725B (es) 2018-04-27
ES2651517T3 (es) 2018-01-26
PT3262932T (pt) 2019-08-26
EP3262932B1 (en) 2019-05-15
IL261239A (en) 2018-10-31
BR112014009259A2 (pt) 2020-10-27
US20200375160A1 (en) 2020-12-03
US20170164590A1 (en) 2017-06-15
EP4311833A3 (en) 2024-05-01
JP6574457B2 (ja) 2019-09-11
AU2012324016B2 (en) 2016-01-28
AU2012324016C1 (en) 2018-02-15
KR20180128494A (ko) 2018-12-03
NZ623456A (en) 2016-05-27
IL252022A0 (en) 2017-06-29
AU2017279797B2 (en) 2020-10-22
PL3262932T3 (pl) 2019-10-31
RS59082B1 (sr) 2019-09-30
WO2013063346A1 (en) 2013-05-02
AU2012324016A8 (en) 2016-03-03
HUE035652T2 (en) 2018-05-28
KR101921126B1 (ko) 2018-11-23
EP3563680A1 (en) 2019-11-06
HK1249712B (zh) 2020-06-26
JP2017143840A (ja) 2017-08-24
NZ719373A (en) 2018-06-29
PT2770821T (pt) 2017-12-18
JP2014532412A (ja) 2014-12-08
PL2770821T3 (pl) 2018-02-28
SI3262932T1 (sl) 2019-09-30
HRP20171761T1 (hr) 2017-12-29
MY178723A (en) 2020-10-20

Similar Documents

Publication Publication Date Title
IL261239B (en) Mice with mhc genetic changes
IL260209B (en) (major histocompatibility complex) mice with genetically modified tissue compatible complex
IL273986B (en) adam6 mice
HK1198171A1 (en) Genetically modified cell receptor mice